Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 in Patients With Renal Cell Carcinoma in the Russian Federation

Ilya Tsimafeyeu,1,2 Galina Alekseeva,3 Maria Berkt,4 Alexander Nosov,4 Igor Myslevtsev,5 Andrey Andrianov,5 Andrey Semenov,6 Pavel Borisov,4 Ruslan Zukov,7 Vadim Goutnik,8 Sergey Savchuk,9 Maria Volkova,10 Maria Mukhina11

Clinical Practice Points

• One-half of patients with renal cell carcinoma infected with severe acute respiratory syndrome coronavirus 2 required hospitalization.
• Eastern Cooperative Oncology Group performance status could be negatively changed in these patients.
• The mortality rate is higher than in people without cancer.
• Some patients could have renal cell carcinoma progression during coronavirus infection.

Introduction

The World Health Organization has announced the pandemic of coronavirus infection 2019 (COVID-19), which can cause acute respiratory syndrome. As of June 13, 2020, Russia ranks third in the incidence of COVID-19 in the world. Patients with cancer are more susceptible to infections owing to systemic immunosuppression caused by malignant neoplasms and by anticancer therapy.1 Patients with renal cell carcinoma (RCC) could also be more sensitive to infections owing to disorders in the immune system.2

The algorithm of the management for patients with RCC in Russia during the coronavirus pandemic was published on the website of the Russian Society of Clinical Oncology on March 24, 2020.3,4 The proposed algorithm was based on the recommendations of professional communities or on information published on the official websites of professional societies, adapted for planning care for patients with RCC during the spread of COVID-19. The main goal of this algorithm was to reduce the risk of COVID-19 contamination, while not affecting the risk of RCC progression or death from kidney cancer. However, some patients with RCC were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we report results from the registry of patients with RCC infected with SARS-CoV-2.

Patients and Methods

Patients were identified for the presence of COVID-19 symptoms or exposure to contacts with known SARS-CoV-2 infection in 9 centers located in the north, central, and east parts of Russia. Anonymized data were obtained by oncologists through an online registry covering demographics, treatments, and outcomes. Patients with RCC were required to have polymerase chain reaction-confirmed COVID-19 disease and were aged ≥18 years at the time of diagnosis. Data for this report were obtained from a retrospective study. All patients provided standard informed consent upon first call to the center.

Results

Between March 10 and June 10, 2020, a total of 37 SARS-CoV-2-positive patients with genitourinary cancers were enrolled.
Seventeen (46%, 8 male and 7 female; mean age, 61.0 years [SD, 9.5 years]) patients had RCC. Almost one-half of the patients had stage IV cancer and multiple metastases, including lung lesions (59%). Thirty-five percent of patients underwent surgery 30 days before confirmed coronavirus infection. The median time from nephrectomy to COVID-19 was 5.2 days. First-line systemic therapy was planned for 18% of patients, but it was not performed owing to COVID-19. Forty-two percent of patients received targeted and immunotherapy at the time of infection, and 28% did not interrupt treatment.

### Table 1

| Characteristics                                      | N (%) |
|------------------------------------------------------|-------|
| No. patients                                        | 17    |
| Mean age, y (range)                                 | 61 (40-81) |
| Gender                                               |       |
| Male                                                 | 8 (47) |
| Female                                               | 9 (53) |
| Stage of RCC                                         |       |
| I                                                    | 5 (29) |
| II                                                   | 1 (6)  |
| III                                                  | 3 (18) |
| IV                                                   | 8 (47) |
| Histology                                            |       |
| Clear-cell RCC                                       | 16 (94) |
| Papillary RCC                                        | 1 (6)  |
| Multiple metastases                                  |       |
| Lung                                                 | 10 (59) |
| Liver                                                | 2 (12) |
| Lymph nodes                                         | 1 (6)  |
| Bone                                                 | 5 (29) |
| Pleura                                               | 1 (6)  |
| Brain                                                | 1 (6)  |
| Surgical treatment at the time of COVID-19           |       |
| Before surgery                                       | 1 (6)  |
| After surgery                                        | 6 (35) |
| Median time from performed surgery to COVID-19, d    | 5.2    |
| Systemic therapy at the time of COVID-19 infection   |       |
| Patients before first-line therapy                   | 3 (18) |
| Patients during first-line therapy                   | 4 (24) |
| Patients during subsequent therapy                   | 3 (18) |
| Sunitinib                                            | 2 (12) |
| Cabozantinib                                         | 2 (12) |
| Nivolumab                                            | 1 (6)  |
| Nivolumab + ipilimumab                               | 1 (6)  |
| Bevacizumab + interferon                             | 1 (6)  |
| Not started (in case of initial planning)            | 3 (18) |
| Interrupted (if the patient was on therapy)          | 5 (29) |
| Continued                                            | 2 (12) |
| Common symptoms of COVID-19                          |       |
| Fever                                                | 12 (71) |
| Cough                                                | 7 (41) |
| Dyspnea                                              | 4 (24) |
| Fatigue                                              | 9 (53) |
| Complications of COVID-19                            |       |
| Pneumonia                                            | 9 (53) |
| Acute respiratory distress syndrome                  | 1 (6)  |
| Respiratory failure                                  | 2 (12) |
| Multiple organ failure                               | 1 (6)  |
| Pancreatitis                                         | 1 (6)  |

### Table 1 Continued

| Characteristics                                      | N (%) |
|------------------------------------------------------|-------|
| ECOG performance status at the time of COVID-19 infection |       |
| 0                                                    | 3 (18) |
| 1                                                    | 3 (18) |
| 2                                                    | 8 (47) |
| 3                                                    | 2 (12) |
| 4                                                    | 1 (6)  |
| The highest value of ECOG performance status for the entire period of COVID-19 |
| 0                                                    | 0      |
| 1                                                    | 3 (18) |
| 2                                                    | 7 (41) |
| 3                                                    | 3 (18) |
| 4                                                    | 3 (18) |
| 5                                                    | 1 (6)  |
| Frequency of ECOG performance status deterioration during COVID-19 |       |
| 0                                                    | 9 (53) |
| Course of COVID-19                                   |       |
| Mild                                                 | 6 (35) |
| Noncritical care hospitalization                     | 5 (29) |
| Critical care hospitalization (oxygen therapy)       | 5 (29) |
| Mechanical ventilation                               | 1 (6)  |
| Median duration of COVID-19, d                       | 21.0   |
| Median length of hospitalization, d                  | 16.2   |
| Antiviral therapy                                    | 7 (41) |
| Hydroxychloroquine                                   | 6 (35) |
| Ritonavir + lopinavir                                 | 1 (6)  |
| COVID-19 disease outcome                             |       |
| Convalescence                                        | 12 (71) |
| Death                                                | 1 (6)  |
| Disease is still ongoing                             | 4 (24) |
| Median time from delay/interruption of treatment owing to COVID-19 to return to treatment, d | 27.6 |
| Clinical or radiologic RCC progression during the COVID-19 disease or within the next 30 days |       |
| Yes                                                  | 1 (6)  |
| No                                                   | 14 (82) |
| No data                                              | 2 (12) |

Abbreviations: COVID-19 = coronavirus infection 2019; ECOG = Eastern Cooperative Oncology Group; RCC = renal cell carcinoma.

Seventeen (46%, 8 male and 7 female; mean age, 61.0 years [SD, 9.5 years]) patients had RCC. Almost one-half of the patients had stage IV cancer and multiple metastases, including lung lesions (59%). Thirty-five percent of patients underwent surgery ≤ 30 days before confirmed coronavirus infection. The median time from nephrectomy to COVID-19 was 5.2 days. First-line systemic therapy was planned for 18% of patients, but it was not performed owing to COVID-19. Forty-two percent of patients received targeted and immunotherapy at the time of infection, and 28% did not interrupt treatment.
Fever, cough, dyspnea, and fatigue were the most common symptoms of COVID-19 disease. Pneumonia, respiratory failure, acute respiratory distress syndrome, multiple organ failure, and pancreatitis developed in 53%, 12%, 6%, 6%, and 6% of cases, respectively. Eastern Cooperative Oncology Group performance status deterioration during COVID-19 was detected in 9 patients. Only 1 patient with coronavirus pneumonia required mechanical ventilation. Noncritical and critical care hospitalizations for COVID-19 symptoms were required in 29% and 29% of patients, respectively. All other patients with RCC had mild symptoms and were managed at home.

Two (11.8%) patients died 3 and 44 days, respectively, after development of COVID-19 symptoms. The median duration of COVID-19 was 21 days, and the median length of hospitalization was 16.2 days. The median time from delay or interruption of treatment (surgery or systemic therapy) owing to COVID-19 to return to the same treatment plan was 27.6 days. Clinical or radiologic RCC progression during the COVID-19 disease or within the next 30 days was detected in 1 patient. Table 1 summarizes patient and treatment characteristics as well as disease outcomes.

**Discussion**

Although this report is limited by small numbers, the results showed that the overall mortality of patients with COVID-19 with kidney cancer was lower (11.8%) than in patients with other malignancies. The TERAVOLT international registry of patients with thoracic tumors and French and Spanish registries demonstrated a higher mortality rate (14.6%-34.6%), and the hospitalization rate in these patients was 72.4% to 76%. In our series, the hospitalization rate was 11% less. Interestingly, the frequency of mechanical ventilation was approximately the same in patients with thoracic tumors (2.5%) and RCC (6%) compared with other studies (21%-35.7%). The length of hospitalization was similar across all registries (range, 12-29.4 days).

Two patients continued antitumor therapy, despite mild symptoms of COVID-19, and did not require hospitalization. However, performance status deterioration was reported in one-half of the patients, even after interruption of anticancer treatment. Also, it should be noted that some patients had RCC progression during coronavirus infection.

Larger studies are needed to evaluate the impact of COVID-19 disease on patients with RCC and genitourinary cancers.

**Disclosure**

Authors are grateful to Pfizer Innovations Russia for scientific support. The authors have stated that they have no conflicts of interest.

**References**

1. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol* 2020; 21:335-7.
2. Porta C, Bonomi L, Lillaz B, et al. Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. *Anticancer Res* 2007; 27:165-73.
3. Tsimafeyeu I, Volkova M. A possible algorithm for managing patients with renal cell carcinoma in the context of a coronavirus infection pandemic (In Russian). Available at: https://rosoncoweb.ru/news/oncology/2020/03/24-1/. Accessed: March 24, 2020.
4. Tsimafeyeu I, Volkova M. Management of patients with renal cell carcinoma during coronavirus pandemic: proposed algorithm in Russia. *Clin Oncol* 2020; 5:1707.
5. Garassino MC. TERAVOLT: first results of a global collaboration to address the impact of COVID-19 in patients with thoracic malignancies 2020, American Association for Cancer Research Virtual Annual Meeting; April 24-29, 2020.
6. Barlesi F, Foulon S, Bayle A, et al. Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments 2020, American Association for Cancer Research Virtual Annual Meeting; April 24-29, 2020.
7. Gomez-Martin C. Adapting oncologic practice to COVID-19 outbreak: from outpatient triage to risk assessment for specific treatment in Madrid, Spain 2020, American Association for Cancer Research Virtual Annual Meeting; April 24-29, 2020.
8. Zhang L, Zhu F, Xie L, et al. The experience of treating patients with cancer during the COVID-19 pandemic in China 2020, American Association for Cancer Research Virtual Annual Meeting; April 24-29, 2020.